KR100505469B1 - 신규한 펩타이드 화합물 및 그 용도 - Google Patents
신규한 펩타이드 화합물 및 그 용도 Download PDFInfo
- Publication number
- KR100505469B1 KR100505469B1 KR10-2002-0080569A KR20020080569A KR100505469B1 KR 100505469 B1 KR100505469 B1 KR 100505469B1 KR 20020080569 A KR20020080569 A KR 20020080569A KR 100505469 B1 KR100505469 B1 KR 100505469B1
- Authority
- KR
- South Korea
- Prior art keywords
- skin
- acid
- lysine
- alginyl
- tryptophanyl
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 26
- 150000001875 compounds Chemical class 0.000 title claims abstract description 22
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract description 34
- 239000004472 Lysine Substances 0.000 claims abstract description 32
- 125000005454 tryptophanyl group Chemical group 0.000 claims abstract description 26
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims abstract description 25
- 230000002087 whitening effect Effects 0.000 claims abstract description 17
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims description 19
- -1 foundation Substances 0.000 claims description 14
- 239000002674 ointment Substances 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 7
- 239000006071 cream Substances 0.000 claims description 7
- 239000006210 lotion Substances 0.000 claims description 4
- 239000006260 foam Substances 0.000 claims description 3
- 239000000344 soap Substances 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims 1
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 abstract description 27
- 230000008099 melanin synthesis Effects 0.000 abstract description 8
- 206010014970 Ephelides Diseases 0.000 abstract description 4
- 101800001751 Melanocyte-stimulating hormone alpha Proteins 0.000 abstract description 4
- 208000003351 Melanosis Diseases 0.000 abstract description 4
- 102100027467 Pro-opiomelanocortin Human genes 0.000 abstract description 4
- 239000005557 antagonist Substances 0.000 abstract description 3
- 210000003491 skin Anatomy 0.000 description 35
- 102400000740 Melanocyte-stimulating hormone alpha Human genes 0.000 description 23
- 101710200814 Melanotropin alpha Proteins 0.000 description 23
- 238000002360 preparation method Methods 0.000 description 22
- 210000002752 melanocyte Anatomy 0.000 description 16
- 230000000052 comparative effect Effects 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Natural products CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 14
- 230000002401 inhibitory effect Effects 0.000 description 13
- 239000004615 ingredient Substances 0.000 description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 239000002537 cosmetic Substances 0.000 description 7
- 239000000686 essence Substances 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 6
- 102000008314 Type 1 Melanocortin Receptor Human genes 0.000 description 6
- 108010021428 Type 1 Melanocortin Receptor Proteins 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 208000012641 Pigmentation disease Diseases 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000019612 pigmentation Effects 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 239000004359 castor oil Substances 0.000 description 4
- 235000019438 castor oil Nutrition 0.000 description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 102000003425 Tyrosinase Human genes 0.000 description 3
- 108060008724 Tyrosinase Proteins 0.000 description 3
- 235000013832 Valeriana officinalis Nutrition 0.000 description 3
- 244000126014 Valeriana officinalis Species 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- 229960001631 carbomer Drugs 0.000 description 3
- 239000011888 foil Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 235000016788 valerian Nutrition 0.000 description 3
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 description 2
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 206010040865 Skin hyperpigmentation Diseases 0.000 description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000011076 sorbitan monostearate Nutrition 0.000 description 2
- 239000001587 sorbitan monostearate Substances 0.000 description 2
- 229940035048 sorbitan monostearate Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- BYHDDXPKOZIZRV-UHFFFAOYSA-N 5-phenylpentanoic acid Chemical compound OC(=O)CCCCC1=CC=CC=C1 BYHDDXPKOZIZRV-UHFFFAOYSA-N 0.000 description 1
- 229930195721 D-histidine Natural products 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 108010000410 MSH receptor Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- FHKPLLOSJHHKNU-INIZCTEOSA-N [(3S)-3-[8-(1-ethyl-5-methylpyrazol-4-yl)-9-methylpurin-6-yl]oxypyrrolidin-1-yl]-(oxan-4-yl)methanone Chemical compound C(C)N1N=CC(=C1C)C=1N(C2=NC=NC(=C2N=1)O[C@@H]1CN(CC1)C(=O)C1CCOCC1)C FHKPLLOSJHHKNU-INIZCTEOSA-N 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 229960004337 hydroquinone Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000003061 melanogenesis Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 231100001068 severe skin irritation Toxicity 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0815—Tripeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
MC1R 10μM | CPM±Std1 | 저해율(%) | |
α-MSH free | negative control group | 6262±854 | 100 |
1nM α-MSH | positive control group | 11146±364 | - |
실시예 1 | 5-phenylvaleric acid-(D)H-R-WNH2 | 8558±153 | 53 |
실시예 2 | 5-phenylvaleric acid-(D)H-R-W-(K)3NH2 | 8063±321 | 63 |
실시예 3 | 5-phenylvaleric acid-(D)H-R-W-(K)6NH2 | 6512±183 | 95 |
실시예 4 | 5-phenylvaleric acid-(D)H-R-W-(K)9NH2 | 6015±231 | 105 |
실시예 5 | 5-phenylvaleric acid-(D)H-R-W-(K)12NH2 | 6123±260 | 103 |
실시예 6 | 5-phenylvaleric acid-(D)H-R-W-(K)15NH2 | 6090±266 | 103 |
실시예 7 | 5-phenylvaleric acid-(D)H-R-W | 8589±195 | 52 |
실시예 8 | 5-phenylvaleric acid-(D)H-R-W-(K)3 | 7965±337 | 65 |
실시예 9 | 5-phenylvaleric acid-(D)H-R-W-(K)6 | 6620±222 | 93 |
실시예 10 | 5-phenylvaleric acid-(D)H-R-W-(K)9 | 6099±285 | 103 |
실시예 11 | 5-phenylvaleric acid-(D)H-R-W-(K)12 | 6285±293 | 100 |
실시예 12 | 5-phenylvaleric acid-(D)H-R-W-(K)15 | 6196±331 | 101 |
MC1R 1μM | CPM±Std1 | 저해율(%) | |
대조군 | 무첨가 | 66034±1972 | - |
실시예 1 | 5-phenylvaleric acid-(D)H-R-WNH2 | 38960±2355 | 41 |
실시예 2 | 5-phenylvaleric acid-(D)H-R-W-(K)3NH2 | 36318±3213 | 45 |
실시예 3 | 5-phenylvaleric acid-(D)H-R-W-(K)6NH2 | 23566±6961 | 64 |
실시예 4 | 5-phenylvaleric acid-(D)H-R-W-(K)9NH2 | 19188±5114 | 71 |
실시예 5 | 5-phenylvaleric acid-(D)H-R-W-(K)12NH2 | 18952±2608 | 71.3 |
실시예 6 | 5-phenylvaleric acid-(D)H-R-W-(K)15NH2 | 19003±2966 | 71.2 |
실시예 7 | 5-phenylvaleric acid-(D)H-R-W | 40062±2683 | 39.4 |
실시예 8 | 5-phenylvaleric acid-(D)H-R-W-(K)3 | 37562±4337 | 43 |
실시예 9 | 5-phenylvaleric acid-(D)H-R-W-(K)6 | 24689±2222 | 63 |
실시예 10 | 5-phenylvaleric acid-(D)H-R-W-(K)9 | 20325±1285 | 70 |
실시예 11 | 5-phenylvaleric acid-(D)H-R-W-(K)12 | 19026±6293 | 71.1 |
실시예 12 | 5-phenylvaleric acid-(D)H-R-W-(K)15 | 21008±2331 | 68.2 |
조성물 | 제조예 1 (중량%) | 비교예 1 (중량%) |
실시예 2의 펩타이드 화합물 | 0.02 | - |
디에틸 세바케이트 | 8 | 8 |
경납 | 5 | 5 |
폴리옥시에틸렌올레일에테르 포스페이트 | 6 | 6 |
벤조산 나트륨 | 적량 | 적량 |
바셀린 | to 100 | to 100 |
조성물 | 제조예 2 (중량%) | 비교예 2 (중량%) | |
실시예 3의 펩타이드 화합물 | 0.01 | - | |
스테아린산 | 1.0 | 1.0 | |
세탄올 | 2.0 | 2.0 | |
피이지-20 소비탄 모노스테아레이트 | 1.0 | 1.0 | |
소비탄 모노스테아레이트 | 1.0 | 1.0 | |
미네랄 오일 | 10.0 | 10.0 | |
트리옥타노에이트 | 5.0 | 5.0 | |
트리에탄올아민 | 0.5 | 0.5 | |
카보머 | 0.2 | 0.2 | |
글리세린 | 5.0 | 5.0 | |
프로필렌글리콜 | 3.0 | 3.0 | |
방부제 | 적량 | 적량 | |
향 | 적량 | 적량 | |
정제수 | to 100 | to 100 |
조성물 | 제조예 3 (중량%) | 비교예 3 (중량%) |
실시예 4의 펩타이드 화합물 | 0.02 | - |
에탄올 | 10.0 | 10.0 |
폴리옥시에틸렌피마자유 | 1.0 | 1.0 |
파라옥시안식향산메틸 | 0.2 | 0.2 |
글리세린 | 5.0 | 5.0 |
1,3-부틸렌글리콜 | 6.0 | 6.0 |
향 | 적량 | 적량 |
색소 | 적량 | 적량 |
정제수 | to 100 | to 100 |
조성물 | 제조예 4 (중량%) | 비교예 4 (중량%) |
실시예 5의 펩타이드 화합물 | 0.05 | - |
프로필렌글리콜 | 10.0 | 10.0 |
글리세린 | 10.0 | 10.0 |
히아루론산나트륨수용액(1%) | 5.0 | 5.0 |
에탄올 | 5.0 | 5.0 |
폴리옥시에틸렌경화피마자유 | 1.0 | 1.0 |
파라옥시안식향산메틸 | 0.1 | 0.1 |
카보머 | 0.3 | 0.3 |
트리에탄올아민 | 0.4 | 0.4 |
향 | 적량 | 적량 |
정제수 | to 100 | to 100 |
조성물 | 제조예 5 (중량%) | 비교예 5 (중량%) |
실시예 9의 펩타이드 화합물 | 0.01 | - |
글리세린 | 5.0 | 5.0 |
프로필렌글리콜 | 4.0 | 4.0 |
폴리비닐알코올 | 15.0 | 15.0 |
에탄올 | 8.0 | 8.0 |
폴리옥시에틸렌경화피마자유 | 1.0 | 1.0 |
폴리옥시에틸렌올레일에틸 | 1.0 | 1.0 |
파라옥시안식향산메틸 | 0.2 | 0.2 |
향 | 적량 | 적량 |
색소 | 적량 | 적량 |
정제수 | to 100 | to 100 |
조성물 | 제조예 6 (중량%) | 비교예 6 (중량%) | |
실시예 10의 펩타이드 화합물 | 0.01 | - | |
폴리옥시에틸렌경화피마자유 | 1.0 | 1.0 | |
파라옥시안식향산메틸 | 적량 | 적량 | |
글리세린 | 6.0 | 6.0 | |
1,3-부틸렌글리콜 | 5.0 | 5.0 | |
카보머 | 0.2 | 0.2 | |
트리에탄올아민 | 0.3 | 0.3 | |
프로필렌글리콜 | 5.0 | 5.0 | |
에탄올 | 3.2 | 3.2 | |
카르복시비닐폴리머 | 18.0 | 18.0 | |
색소 | 적량 | 적량 | |
향 | 적량 | 적량 | |
정제수 | to 100 | to 100 |
실험물질 | 뚜렷한저해효과(명) | 저해효과있음(명) | 저해효과없음(명) | 부작용(명) |
제조예 1 | 7 | 10 | 3 | 0 |
제조예 2 | 8 | 10 | 2 | 0 |
제조예 3 | 9 | 9 | 2 | 0 |
제조예 4 | 11 | 6 | 3 | 0 |
제조예 5 | 9 | 7 | 4 | 0 |
제조예 6 | 7 | 9 | 4 | 0 |
Claims (5)
- 하기 일반식 1로 표시되는 5-페닐 발러릭 산-(D)히스티딜 알지닐 트립토파닐(라이신)n{5-Phenylvaleric acid-(D)His-Arg-Trp-(Lys)n} 펩타이드 화합물.<일반식 1>상기 일반식 1에서, n은 0 내지 21로부터 선택된 정수이고, R은 OH 또는 NH2임.
- 삭제
- 제1항의 펩타이드 화합물을 유효성분으로 함유하는 것을 특징으로 하는 피부미백용 조성물.
- 제3항에 있어서, 상기 펩타이드 화합물의 함량은 조성물 총 중량을 기준으로 0.00001 내지 10중량%인 것을 특징으로 하는 피부미백용 조성물.
- 제3항에 있어서, 상기 피부미백용 조성물은 스킨, 로션, 크림, 파운데이션, 에센스, 젤, 팩, 폼 클렌징, 비누 및 피부외용 연고로 이루어진 군으로부터 선택된 어느 하나의 제형으로 이루어진 것을 특징으로 하는 피부미백용 조성물.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2002-0080569A KR100505469B1 (ko) | 2002-12-17 | 2002-12-17 | 신규한 펩타이드 화합물 및 그 용도 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2002-0080569A KR100505469B1 (ko) | 2002-12-17 | 2002-12-17 | 신규한 펩타이드 화합물 및 그 용도 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20040052389A KR20040052389A (ko) | 2004-06-23 |
KR100505469B1 true KR100505469B1 (ko) | 2005-08-05 |
Family
ID=37346059
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2002-0080569A KR100505469B1 (ko) | 2002-12-17 | 2002-12-17 | 신규한 펩타이드 화합물 및 그 용도 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100505469B1 (ko) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108129551B (zh) * | 2017-03-28 | 2020-03-31 | 温州千瑞生物科技有限公司 | 具有皮肤美白效果的肽及其用途 |
-
2002
- 2002-12-17 KR KR10-2002-0080569A patent/KR100505469B1/ko active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
KR20040052389A (ko) | 2004-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11896704B2 (en) | Compounds useful for the treatment and/or care of the skin, hair, nails and/or mucous membranes | |
KR100855457B1 (ko) | 악틴, 악티게닌 또는 그의 혼합물을 유효성분으로 함유하는피부미백용 화장료 조성물 | |
JP2003238387A (ja) | 目の下のたるみおよびくまを緩和するための皮膚外用剤組成物 | |
CN102395598A (zh) | 用于治疗和/或护理皮肤和/或毛发的肽、及其在化妆用组合物或药物组合物中的用途 | |
KR100760875B1 (ko) | 멜라닌 생성 억제 피부미백용 화장품 조성물 | |
BRPI0609745A2 (pt) | uso de composição cosmética ou dermofarmacêutica que compreende peptìdeos derivados de encefalinas para reduzir e/ou elminar rugas faciais | |
KR100479741B1 (ko) | 글루코오스 아실화 유도체 또는 수크로오스 아실화유도체를 함유하는 피부미백제 | |
CN113893184A (zh) | 一种多肽美白祛斑组合物、及护肤品和制备方法 | |
US5126327A (en) | Melanocyte-stimulating hormone inhibitor and external preparation containing the same | |
JP2001019607A (ja) | 皮膚化粧料 | |
KR100497151B1 (ko) | 신규한 펩타이드 화합물 및 그 용도 | |
KR100505469B1 (ko) | 신규한 펩타이드 화합물 및 그 용도 | |
GB2339390A (en) | Melaninization inhibitor,skin-care preparation,and bath agent | |
JPH0987164A (ja) | 皮膚外用剤 | |
US20030087833A1 (en) | Topical composition for skin | |
KR100679878B1 (ko) | 멜라노사이트-자극 호르몬 억제제 | |
KR20030061167A (ko) | 베라트라민을 함유하는 피부미백용 조성물 | |
KR100757130B1 (ko) | 멜라닌 생성 억제 활성을 갖는 베라진 및 에피-베라진을함유하는 피부미백용 화장료 | |
KR100843168B1 (ko) | 올리고뉴클레오타이드를 포함하는 미백제 | |
JP3113407B2 (ja) | 化粧料 | |
WO2024106588A1 (ko) | 피부 상태 개선 활성을 갖는 펩타이드 및 이의 용도 | |
JPH08217620A (ja) | メラニン生成抑制剤及び皮膚化粧料 | |
KR102022621B1 (ko) | 스워티아자포닌을 포함하는 피부 주름 개선용 조성물 | |
KR20160119548A (ko) | 현삼 온수 추출물을 유효성분으로 함유하는 피부미백용 조성물 | |
KR0180684B1 (ko) | 포토라이에이즈를 함유한 피부미백용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130617 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20140703 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20150612 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20160630 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20180627 Year of fee payment: 14 |
|
FPAY | Annual fee payment |
Payment date: 20190702 Year of fee payment: 15 |